ADPT - Adaptive Biotechnologies Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
29.65
-0.35 (-1.17%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close30.00
Open30.02
Bid0.00 x 1200
Ask0.00 x 1300
Day's Range28.94 - 30.74
52 Week Range24.05 - 55.12
Volume1,798,044
Avg. Volume1,179,254
Market Cap3.713B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.51
Earnings DateFeb 25, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est44.75
  • GlobeNewswire

    Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2019 Financial Results

    SEATTLE, Feb. 26, 2020 -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the.

  • MEDNAX (MD) Q4 Earnings and Revenues Surpass Estimates
    Zacks

    MEDNAX (MD) Q4 Earnings and Revenues Surpass Estimates

    Mednax's (MD) Q4 results reflect growth in same unit revenues and lower general and administrative expenses.

  • GlobeNewswire

    Adaptive Biotechnologies to Present at the 40th Annual Cowen Health Care Conference

    Adaptive Biotechnologies Corporation (ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the company will be participating in the upcoming 40th Annual Cowen Health Care Conference in Boston, MA. Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease.

  • GlobeNewswire

    Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2019 Financial Results on February 26, 2020

    Adaptive Biotechnologies Corporation (ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that it will report financial results for the fourth quarter and full year of 2019 after market close on Wednesday, February 26, 2020. Investors interested in listening to the conference call may do so by dialing (800) 361-2311 for U.S. callers or (409) 937-8761 for international callers (Conference ID: 8845168). Adaptive Biotechnologies is a commercial-stage biotech company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease.

  • Why Earnings Season Could Be Great for Adaptive (ADPT)
    Zacks

    Why Earnings Season Could Be Great for Adaptive (ADPT)

    Adaptive (ADPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

  • Andreas Halvorsen Trims Adaptive Biotechnologies Stake
    GuruFocus.com

    Andreas Halvorsen Trims Adaptive Biotechnologies Stake

    The immune-driven biotech company went public last June Continue reading...

  • Insiders Roundup: Texas Instruments, Homolody Medicines
    GuruFocus.com

    Insiders Roundup: Texas Instruments, Homolody Medicines

    Largest insider trades of the week Continue reading...

  • Thermo Fisher Scientific Could Trade Higher in the Weeks and Months Ahead
    TheStreet.com

    Thermo Fisher Scientific Could Trade Higher in the Weeks and Months Ahead

    Tuesday night's fast-paced 'Lightning Round' segment of Mad Money had one caller asking about Adaptive Biotechnologies : "I like Danaher more and I like Thermo Fisher Scientific more," said Jim Cramer. In this daily bar chart of TMO, below, we can see that prices have moved higher in an uptrend the past year. Trading volume looks like it has decreased since early October but the daily On-Balance-Volume (OBV) line shows a nice rise for the year.

  • GlobeNewswire

    Adaptive Announces Pricing of Public Offering of Common Stock

    Adaptive Biotechnologies Corporation (ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today the pricing of its underwritten public offering of 8,000,000 shares of its common stock by certain selling shareholders at a public offering price of $26.50 per share, before underwriting discounts and commissions. In addition, the selling shareholders have granted the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. Adaptive will not receive any proceeds from the sale of the shares of common stock by the selling shareholders.

  • Benzinga

    The Daily Biotech Pulse: Johnson & Johnson Earnings, FDA Nod For Horizon Therapeutics, Slew Of Secondary Offerings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 21) Abbott Laboratories (NYSE: ABT ) Apellis Pharmaceuticals ...

  • GlobeNewswire

    Adaptive Announces Proposed Public Offering of Common Stock

    Adaptive Biotechnologies Corporation (ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today the commencement of a proposed underwritten public offering of 8,000,000 shares of its common stock by certain selling shareholders. In addition, certain selling shareholders expect to grant the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of its common stock in the offering. Adaptive will not receive any of the proceeds from the sale of the shares of its common stock being offered by the selling shareholders.

  • GlobeNewswire

    Adaptive Announces Preliminary Unaudited Revenue for Full Year 2019

    Adaptive Biotechnologies Corporation (ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today preliminary unaudited revenue for the full year 2019. “We are pleased with our strong performance in the fourth quarter, as we continued accelerating our efforts to scale our business to aggressively pursue the large pipeline opportunity in front of us,” said Chad Robins, CEO and co-founder of Adaptive Biotechnologies.

  • GlobeNewswire

    Adaptive and Genentech Partner to Use clonoSEQ® Assay to Measure Minimal Residual Disease as a Primary Endpoint in Phase III Study of Chronic Lymphocytic Leukemia Patients

    Adaptive Biotechnologies Corporation (ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a multi-year, global diagnostic agreement with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) to utilize Adaptive’s next-generation sequencing (NGS)-based clonoSEQ® Assay to assess minimal residual disease (MRD) status in response to venetoclax in the registrational Phase III CRISTALLO (CO41685) study for the treatment of newly diagnosed people with chronic lymphocytic leukemia (CLL) plus additional future venetoclax studies in CLL. Adaptive and Genentech will partner to incorporate the clonoSEQ Assay to measure MRD status as a primary endpoint in this registrational study.

  • GlobeNewswire

    Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Monitoring MRD in Patients With Chronic Lymphocytic Leukemia

    Adaptive Biotechnologies Corporation (ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses diagnostic technologies through its MolDX program, has expanded coverage of the clonoSEQ Assay to include monitoring minimal residual disease (MRD) in Medicare patients with chronic lymphocytic leukemia (CLL). This adds to existing Medicare coverage in B-cell acute lymphoblastic leukemia (ALL) and multiple myeloma, which was established in January 2019.

  • GlobeNewswire

    Adaptive Biotechnologies to Present at the 38th Annual J.P. Morgan Healthcare Conference

    Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (ADPT), today announced the company will be participating in the upcoming 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease.

  • Top Ranked Momentum Stocks to Buy for December 30th
    Zacks

    Top Ranked Momentum Stocks to Buy for December 30th

    Top Ranked Momentum Stocks to Buy for December 30th

  • Tech will drive change in health care throughout next decade
    American City Business Journals

    Tech will drive change in health care throughout next decade

    Partnerships between tech companies and those in health care and biotech will change how Americans use health care in the 2020s, experts predict.

  • Is Adaptive Biotechnologies Corporation (ADPT) A Good Stock To Buy?
    Insider Monkey

    Is Adaptive Biotechnologies Corporation (ADPT) A Good Stock To Buy?

    The market has been volatile in the last few months as the Federal Reserve finalized its rate cuts and uncertainty looms over trade negotiations with China. Small cap stocks have been hit hard as a result, as the Russell 2000 ETF (IWM) has underperformed the larger S&P 500 ETF (SPY) by more than 10 percentage […]

  • Chad Robins led Adaptive Biotechnologies through a huge 2019
    American City Business Journals

    Chad Robins led Adaptive Biotechnologies through a huge 2019

    Chad Robins, CEO and president of Adaptive Biotechnologies, led the Seattle company through one of the largest biotech IPOs of the year. Its mission is to map the human immune system to identify and treat diseases. “We went public because we had a tremendous business opportunity to execute on our vision of the immune medicine platform,” Robins said.

  • Adaptive Biotechnologies Shares March Higher, Can It Continue?
    Zacks

    Adaptive Biotechnologies Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor Adaptive Biotechnologies.

  • Fiverr Languishes Below IPO Price as First Chance to Sell Nears
    Bloomberg

    Fiverr Languishes Below IPO Price as First Chance to Sell Nears

    (Bloomberg) -- Fiverr International Ltd.’s initial zing has almost entirely faded since its June IPO, with the stock falling for six straight days to below its IPO price as insiders’ and early investors’ first chance to sell looms on Tuesday.The biggest stakeholders include Viola Private Equity’s Jonathan Kolber, Deer VII & Co., Accel London III Associates, Square Peg Group, and co-founder and chief executive officer Micha Kaufman, according to data compiled by Bloomberg. But post-IPO stock weakness, with shares off the June high of $44 by more than 52%, make it less likely shareholders will walk away.Fiverr chief Kaufman was unavailable to respond to queries.The operator of an online marketplace for software services had the fourth-best debut of this year’s 239 IPOs, rising a whopping 90% from offer to its first close. That ranks just behind Beyond Meat Inc., Adaptive Biotechnologies Corp., and Cortexyme Inc., each of which has done better hanging on to initial gains. Underwriters on the Fiverr IPO were JPMorgan, Citi, BofA, UBS, Oppenheimer, Needham, and JMP Securities.Analysts appear split, with four buy, three hold and no sell ratings on the stock, according to data compiled by Bloomberg. But with price targets ranging from $22 to $34, they seem to agree that debut highs are unlikely to be seen again anytime soon. To contact the reporter on this story: Crystal Kim in New York at ckim426@bloomberg.netTo contact the editors responsible for this story: Brad Olesen at bolesen3@bloomberg.net, Scott SchnipperFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • GlobeNewswire

    Adaptive and AbbVie Partner Across Multiple Myeloma Trials to Measure Minimal Residual Disease Using the clonoSEQ® Assay

    Adaptive Biotechnologies Corporation (ADPT) today announced a multi-year, global collaboration agreement with AbbVie (ABBV) to utilize Adaptive’s next-generation sequencing (NGS)-based clonoSEQ® Assay to assess minimal residual disease (MRD) status in response to venetoclax across multiple myeloma (MM) clinical trials. “Adaptive is thrilled to partner with AbbVie to support the clinical development and potential regulatory approval of venetoclax in multiple myeloma,” said Chad Robins, CEO and co-founder of Adaptive Biotechnologies. MRD is a measure of the amount of cancer in the body, specifically the very small number of cancer cells that remain during or after treatment.

  • GlobeNewswire

    Adaptive Biotechnologies and Collaborators to Present Data from More Than 25 clonoSEQ® Abstracts at ASH 2019 Demonstrating Clinical Relevance of Standardized, Accurate MRD Testing for Blood Cancer Patients

    Research and real-world evidence support the use across a range of leukemias and lymphomas and demonstrate utility in multiple tissue types, including blood and bone marrow.

  • Hedge Funds Love Echostar Corporation (SATS) Way More Than These 4 Stocks
    Insider Monkey

    Hedge Funds Love Echostar Corporation (SATS) Way More Than These 4 Stocks

    The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 700 world-class investment firms that we track and now have access to the collective wisdom contained in […]

  • Seattle has potential as a biotech hub, but more companies must stay here and grow
    American City Business Journals

    Seattle has potential as a biotech hub, but more companies must stay here and grow

    Seattle's biotech community has a reputation for developing companies that are eventually acquired and that has restricted its growth. But a few companies are well-positioned to change that narrative.